A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis
Completed · Phase 3 · NCT03725202
Conditions: Giant Cell Arteritis (GCA)
At a glance
- Research payments reported, 2025
- $17,447
- U.S. investigators named
- 3
- Sites paid
- 3
- Planned or actual enrollment
- 429
About the trial
- Sponsor
- AbbVie
- Tested
- Upadacitinib (drug), Corticosteroid (CS) (drug), Placebo (other)
- Dates
- Started 2019-01-24; completion 2025-03-11
- Results posted
- Yes
This study consists of two periods. The objective of Period 1 is to evaluate the efficacy of upadacitinib in combination with a 26-week corticosteroid (CS) taper regimen compared to placebo in combination with a 52-week CS taper regimen, as measured by the proportion of participants in sustained remission at Week 52, and to assess the safety and tolerability of upadacitinib in participants with giant cell arteritis (GCA). The objective of Period 2 is to evaluate the safety and efficacy of continuing versus withdrawing upadacitinib in maintaining remission in participants who achieved sustained remission in Period 1.
From ClinicalTrials.gov, last updated 2026-02-24. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $17,447 in research payments for this study in 2025 (6 payments).
Products named: Rinvoq
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Joel Block, M.D. Rheumatology · Chicago, IL
- William E. Davis Rheumatology · New Orleans, LA
- Peter A. Merkel, MD, MPH Rheumatology · Radnor, PA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.